Divalproex Sodium Tablet, Extended Release
Product Images NDC 55154-2345

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-2345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (283af6d2 8ea2 4225 B2e7 A2057dbdb793 00)

Bag Label (283af6d2 8ea2 4225 B2e7 A2057dbdb793 00)
Divalproex Sodium Extended-Release Tablets are available in a package of 10 tablets. Each tablet has a valproic acid activity of 500mg and is coated with a film. The package insert includes prescribing information, precautions, and warnings. The medication should be stored at a temperature of between 20-25°C. This package is not suitable for child-resistant storage and is exclusively intended for institutional use. There are multiple companies involved in the production and distribution of this medication.*
FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

10 (Divalproex Sodium Extended Release Tablets Usp 1)
FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)
FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)
This appears to be a graph showing the % Reduction in CPS (Chronic Pelvic Syndrome) Rate for patients who were administered High Dose and Low Dose Divalproex Sodium. The graph indicates that the High Dose had a higher percentage (around 100%) of patient improvement in CPS rate in comparison to the Low Dose (around 50%). The graph also shows the percentage of patients who experienced No Change and Worsening in their CPS rate.*
FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.